SCHEMBL5270664

SCHEMBL5270664

CCc1cc(-c2n[nH]cc2-c2ccc(Br)cc2)c(O)cc1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.47
NPSR1 Q6W5P4 3/20 0.47
MAPK1 P28482 3/20 0.47
ATM Q13315 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
MEN1 O00255 5/20 0.44
KMT2A Q03164 5/20 0.44
GAA P10253 5/20 0.44
HSP90AA1 P07900 12/20 0.43
HSP90AB1 P08238 5/20 0.43
TDP1 Q9NUW8 2/20 0.42
MET P08581 1/20 0.42
PIM1 P11309 1/20 0.42
LTK P29376 1/20 0.42
ALOX12 P18054 3/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.41
POLB P06746 1/20 0.41
LMNA P02545 4/20 0.40
SMN1; SMN2 Q16637 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5271241 0.86 HSP90AA1 (0.49) MAPTNPSR1MAPK1MEN1KMT2A
SCHEMBL14396113 0.86 MEN1 (0.61) MAPTNPSR1MEN1KMT2AGAA
SCHEMBL5272655 0.81 MEN1 (0.45) MAPTNPSR1MAPK1ATML3MBTL1
SCHEMBL5267807 0.80 HSP90AA1 (0.44) MAPTNPSR1KMT2AHSP90AA1HSP90AB1
SCHEMBL14396291 0.79 HSP90AA1 (0.62) MAPTNPSR1MAPK1MEN1KMT2A
SCHEMBL14395889 0.78 HSP90AA1 (0.67) MAPTNPSR1MAPK1MEN1KMT2A
SCHEMBL5271077 0.76 GPR55 (0.57) MAPTNPSR1MAPK1MEN1KMT2A
SCHEMBL1528261 0.76 GAA (0.60) MAPTNPSR1MEN1KMT2AGAA
SCHEMBL4310608 0.75 GAA (0.41) MAPTNPSR1MAPK1MEN1KMT2A
SCHEMBL14396294 0.74 MEN1 (0.54) MAPTNPSR1MAPK1ATML3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1456180-B1 3-(2,4)DIHYDROXYPHENYL-4-PHENYLPYRAZOLES AND THEIR MEDICAL USE VERNALIS CAMBRIDGE LTD (GB) 2007-10-03 EP disclosed
EP-1456180-B1 3-(2,4)DIHYDROXYPHENYL-4-PHENYLPYRAZOLES AND THEIR MEDICAL USE VERNALIS CAMBRIDGE LTD (GB) 2007-10-03 EP disclosed
US-7247734-B2 3,4-diarylpyrazoles and their use in the therapy of cancer VERNALIS (CAMBRIDGE) LIMITED (GB) 2007-07-24 US disclosed
US-7247734-B2 3,4-diarylpyrazoles and their use in the therapy of cancer VERNALIS (CAMBRIDGE) LIMITED (GB) 2007-07-24 US disclosed
US-20050222230-A1 3,4-diarylpyrazoles and their use in the therapy of cancer VERNALIS (CAMBRIDGE) LIMITED (GB) 2005-10-06 US disclosed
EP-1456180-A1 3,4-DIARYLPYRAZOLES AND THEIR USE IN THE THERAPY OF CANCER Vernalis (Oxford) Ltd (GB) 2004-09-15 EP disclosed
WO-2003055860-A1 3,4-DIARYLPYRAZOLES AND THEIR USE IN THE THERAPY OF CANCER VERNALIS (CAMBRIDGE) LIMITED (GB) 2003-07-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222230-A1 3,4-diarylpyrazoles and their use in the therapy of cancer HSP90AB1, HSP90AA1, HSP90AB2P MAPT 4683/4885NPSR1 2685/4885MAPK1 2961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.